Comparative Pharmacology
Head-to-head clinical analysis: MICROSUL versus SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROSUL versus SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE.
MICROSUL vs SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
Sulfacetamide sodium inhibits bacterial dihydropteroate synthase, blocking folate synthesis; prednisolone sodium phosphate suppresses inflammation by binding glucocorticoid receptors, inhibiting phospholipase A2 and pro-inflammatory cytokine production.
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
1-2 drops into the conjunctival sac of the affected eye(s) every 2-4 hours during the day and at bedtime; frequency may be decreased as clinical signs improve.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours; prolonged in renal impairment
Sulfacetamide: 6-8 hours (prolonged in renal impairment). Prednisolone: 2-4 hours (terminal half-life). Clinically, systemic effects may persist longer due to tissue distribution.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Renal excretion of unchanged sulfacetamide (60-75%) and prednisolone metabolites (primarily conjugated); minimal biliary/fecal elimination (<10% for each).
Category C
Category A/B
Sulfonamide Antibiotic
Sulfonamide Antibiotic